^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Regimen: | FOLFIRINOX (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX
Published date:
10/09/2018
Excerpt:
Mutations were seen in BRCA1 (N = 7), BRCA2 (N = 5), BRCA1/2 (N = 3), PALB2 (N = 3), MSH2 (N = 1) and FANCF (N = 1) of all the DDR genes sequenced...Cox regression (HR 0.37 [0.15-0.94], p = 0.04) showed presence of DDRGM was associated with improved OS....we found that the presence of germline and somatic DDRGM as well as germline BRCA1/2 mutations are associated with improved OS in PDAC patients treated with FOLFIRINOX.
DOI:
10.1093/annonc/mdy282.100
Source:
Title:
Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX
Published date:
04/29/2022
Excerpt:
A woman in her 50s...was diagnosed with stage IV pancreatic ductal adenocarcinoma (PDAC) metastatic to the liver and was found to harbour a BRCA1 germline mutation. She had palliative chemotherapy, initially with 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, and then FOLFIRI and capecitabine, achieving a sustained near-complete response for at least 86 months.
Secondary therapy:
FOLFIRI + capecitabine
DOI:
http://dx.doi.org/10.1136/bcr-2022-249370
